Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

Atara Biotherapeutics, Inc., also known as ATRA, is a company specializing in the development of T-cell immunotherapies for the treatment of cancer and autoimmune diseases. The company's platform is based on the use of allogeneic T-cells, which are cells derived from a donor rather than the patient. This approach allows for the rapid delivery of a T-cell immunotherapy product, which is manufactured in advance and stored in inventory for numerous potential patients.

Atara's main business activities involve the development of T-cell immunotherapies for various indications. The company's pipeline includes several programs, such as tab-cel, an allogeneic EBV-specific T-cell immunotherapy approved in the European Union and the United Kingdom for the treatment of EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). The company is also developing ATA3219, an allogeneic CD19 CAR T immunotherapy targeting B-cell malignancies and autoimmune diseases, and ATA3431, an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease. Additionally, Atara has a preclinical program, ATA188, an allogeneic T-cell immunotherapy targeting EBV antigens for the potential treatment of multiple sclerosis (MS).

Atara generates revenue through its partnerships and collaborations, including its commercialization agreement with Pierre Fabre for the development and commercialization of tab-cel in Europe and other countries. The company has also partnered with HCRx, a private investment firm, to sell a portion of its rights to receive royalties and certain milestones in tab-cel. Atara's competitive advantages include its proprietary allogeneic T-cell platform, which provides a potential best-in-class profile with off-the-shelf availability, enhanced functional persistence, polyfunctional phenotype, and efficient targeting of CD19-expressing tumor cells.

Atara's customers include several leading academic institutions, such as Memorial Sloan Kettering Cancer Center and the Council of the Queensland Institute of Medical Research. The company's products are also being developed in collaboration with pharmaceutical companies, including Pierre Fabre and HCRx.

The company's proprietary brands and trade names include tab-cel, ATA3219, and ATA3431. Atara's competitive landscape includes numerous pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. The company seeks to protect its proprietary position through patent applications, regulatory filings, trademarks, trade secrets, and continuing technological innovation.